MedTrace Logo

Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

NCT06534463 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-12-03

No results posted yet for this study

Summary

This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.

Conditions

Interventions

OTHER

All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.

The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-02
Primary Completion
2029-03-01
Completion
2029-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06534463 on ClinicalTrials.gov